Elevation of MAP2 in breast cancer cell lines leads to increased paclitaxel sensitivity, and gene expression analysis revealed that MAP2 had significantly higher levels of expression in patients achieving a pathologic complete response to neoadjuvant paclitaxel with radiation treatment [56]. This evidence concerns the gene MAP2 and breast cancer.